The line graph shows that, among closed treatment episodes for client’s own drug use for amphetamines, methamphetamines have been the most common drug of concern since 2012–13. In 2021–22, there were 39,912 (80.3%) episodes with methamphetamines as a principal drug of concern, a large increase from 4,050 (18.2%) episodes in 2012-13.
The number and proportion of episodes with amphetamines not further defined has fallen from 15,210 episodes (68.3%) in 2012–13 to 7,685 episodes (15.5%) in 2021–22.
The number and proportion of episodes with amphetamine has fluctuated, peaking in 2013–14 (6,579 episodes or 22.7%) and falling to 1,345 episodes (2.7%) in 2021–22.
The number and proportion of episodes with other amphetamines has increased from 177 episodes in 2012–13 (0.8%) to 752 episodes in 2021–22 (1.5%).